Share

August 2020; 6 (4) Clinical/Scientific NotesOpen Access

SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes

Martin Paucar, Tobias Granberg, Kristina Lagerstedt-Robinson, Elisabet Waldenlind, Sven Petersson, Love Nordin, Per Svenningsson
First published July 7, 2020, DOI: https://doi.org/10.1212/NXG.0000000000000474
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
358

Share

Article Figures & Data

Figures

  • Figure 1
    Figure 1 Spectroscopy of the index case before (A) and after treatment (B)

    The T2-weighted images to the right show the location of a 30 × 20 × 20 mm volume of interest in a midsagittal, coronal, and transverse plane. The described voxel was averaged 200 times, and the resulting 1H-MR spectrum is displayed to the left where the main peaks for glutamine and glutamate have been highlighted. In the first measurement, A, the Glx concentration was measured to 3.865 mmoL/kg (SD 10%) in the left frontoparietal region. In the second measurement, B, Glx concentration was measured to 4.580 mmoL/kg (SD 11%).

Tables

  • Table1
  1. Martin Paucar, MD, PhD,
  2. Tobias Granberg, MD, PhD,
  3. Kristina Lagerstedt-Robinson, PhD,
  4. Elisabet Waldenlind, MD, PhD,
  5. Sven Petersson, PhD,
  6. Love Nordin, PhD and
  7. Per Svenningsson, MD, PhD
  1. From the Department of Neurology (M.P., E.W., P.S.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., T.G., E.W., P.S.), Karolinska Institutet; Department of Neuroradiology (T.G.), Karolinska University Hospital; Department of Molecular Medicine and Surgery (K.L.-R.), Karolinska Institutet; Department of Clinical Genetics (K.L.-R.); Medical Radiation Physics and Nuclear Medicine (S.P., L.N.), Karolinska University Hospital; and Division of Clinical Geriatrics (L.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  1. Correspondence
    Dr. Paucar martin.paucar-arce{at}sll.se
Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. (1) Stockholm Region

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. Research grants, 3 years, Stockholm Region and Karolinska Institutet (ALF 20170036, CIMED 20190565).

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. Research grant, 4 years, The Swedish Society for Medical Research. Research grant, The Christer Lindgren and Eva Fredholm Foundation.

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. Payment 15,000 SEK by Novartis for 3 lectures october 2019 given for the Swedish Headache Sociaty. Novartis sponsored the lectures

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. CBD solutions AB

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. Sanofi Genzyme, Shire

Editorial Boards:

  1. PLoS ONE, Academic editor, 2012-2017 Neuropharmacology, Academic editor, 2016-2017

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. Swedish Research Council 2016_2019 ALF Stockholm 2017_2019 Wallenberg Clinical Scholar 2017_2021

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Familial hemiplegic migraine (FHM) is a group of rare familial disorders caused, in most cases, by mutations in CACNA1A and ATP1A2.1 Heterozygous mutations in solute carrier family 1 member 3 (SLC1A3), encoding glial glutamate transporter, are associated with episodic ataxia type 6 (EA6).2,–,5 In addition to episodic ataxia (EA), alternating hemiplegia and hemiplegic migraine have been reported twice in patients with EA6.2,4 Mutations in SLC1A3 are very rare; screenings in cohorts of EA and alternating hemiplegia have yielded either negative results3,6,–,8 or variants of unclear significance.e-1--e-3 Herein, we characterize a patient featuring sporadic hemiplegic migraine (SHM) responsive to acetazolamide (ACZ) and mild cerebellar atrophy associated with a new variant in SLC1A3. We also report the utility of proton magnetic resonance spectroscopy (MRS) for this condition.

Methods

The index case and her mother (figure e-1, doi:10.5061/dryad.v41ns1rsd) were evaluated after providing oral and written consent for this study, which was approved by the Regional Ethics Committee of Stockholm. Patients underwent clinical evaluation, structural imaging with MRI, and genotyping. The index case underwent neurophysiologic tests and proton MRS before and after treatment with ACZ. MRS was also performed in 20 healthy controls (data available from Dryad [appendix, doi:10.5061/dryad.v41ns1rsd]).

Results

Patient II:1

The index case is a female 24-year-old medical student with roots in the Middle East and born to consanguineous parents. She was diagnosed with polycystic ovarian syndrome. She was affected by recurrent episodes of left-side hemiplegic spells triggered often by menstruation but also by stress and preceded by a sensorimotor march. Only occasionally these spells affected the right side. Onset was at age 18 years; those episodes occurred twice per year and lasted for up to 2 hours. On one occasion, she had hemiparesis for 9 hours; migraine without aura preceded the hemiplegia spells by 1 to 2 days. The patient did not have any visual complaints during the attacks either; she reported numbness in the hemiparetic side during the entire hemiplegic episode. Examination during 1 episode that motivated admission demonstrated left-sided hemiparesis but normal visual fields and absence of ataxia. The patient did not have any visual complaints during the attacks either; however, any visual aura may well have disappeared by the time she came to the hospital. Interictally, the patient had gaze-evoked nystagmus (GEN), and EEG and electroneurography were normal. Pathologic CAG expansions in CACNA1A and conventional mutations in CACNA1A, ATP1A2, and SCN1A were ruled out. A targeted analysis revealed the novel variant c379_383del in SLC1A3. This sequence variant leads to a truncating protein (p.Tyr127Aspfs*60) and is absent in databases (The Genome Aggregation Database [gnomAD], ClinVar, and The Human Gene Mutation Database). Other sequence variants leading to haploinsufficiency are otherwise rare in the normal population (gnomAD). Treatment with ACZ (250 mg twice daily) prevented hemiplegic spells and interictal GEN receded. This therapeutic benefit has lasted for more than 1.5 years, and the patient decided to interrupt this treatment to avoid polypharmacy. MRI of her brain demonstrated mild vermian atrophy (figure e-2, doi:10.5061/dryad.v41ns1rsd). The index case went through MRS during an interictal period before and after treatment with ACZ (figure 1). MRS demonstrated low Glx (combined glutamate and glutamine) peak (3.865 mmol/kg, SD 10%) and nominally higher levels (4.580 mmol/kg, SD 11%) in the parietal lobe after treatment with ACZ was initiated (data available from Dryad: doi:10.5061/dryad.v41ns1rsd [table e-2, doi:10.5061/dryad.v41ns1rsd]). At age 23 years, the proband developed Cushing syndrome due to an adrenocortical carcinoma, which motivated a right-side nephrectomy and adrenalectomy. Further investigation revealed 2 lung metastases that were resected; recently, one of these metastases has relapsed.

Figure 1
Figure 1 Spectroscopy of the index case before (A) and after treatment (B)

The T2-weighted images to the right show the location of a 30 × 20 × 20 mm volume of interest in a midsagittal, coronal, and transverse plane. The described voxel was averaged 200 times, and the resulting 1H-MR spectrum is displayed to the left where the main peaks for glutamine and glutamate have been highlighted. In the first measurement, A, the Glx concentration was measured to 3.865 mmoL/kg (SD 10%) in the left frontoparietal region. In the second measurement, B, Glx concentration was measured to 4.580 mmoL/kg (SD 11%).

Patient I:1

This patient is a 50-year-old woman who meets the criteria for migraine with visual aura e-4 but denies hemiplegic and ataxia episodes. Her examination and brain MRI were normal; she declined MRS and neurophysiologic tests (table e-1, doi:10.5061/dryad.v41ns1rsd).

Discussion

Hemiplegic migraine in association with a SLC1A3 variant has not been reported before to the best of our knowledge. Despite mild cerebellar atrophy, only interictal nystagmus was found in the index case. Of note, penetrance was reduced in our family; the parent carrying the variant has migraine, which was also reported for the variants p.Cys186Ser and p.Trp387Pro.3,4 The long latency between onset of SHM and Cushing syndrome strongly argues against a paraneoplastic syndrome. A correlation between the degree of glutamate reuptake and clinical severity has been suggested,3 but the theoretical haploinsufficiency in our family challenges that hypothesis. A dominant negative effect has been demonstrated for the variants p.Pro290Arg, whereas a clear loss of function was described for p.Trp387Pro.2,4 Similar to our case, large deletions in CACNA1A cause EA 2 possibly by means of haploinsufficiency.e-5 De Fusco et al. proposed a similar mechanism in FHM2.e-6 Two reported SLC1A3 variantse-1–e-3 are likely benign considering their frequency in the normal population (gnomAD). Factors modulating variable expressivity and reduced penetrance of SLC1A3 variants are unknown. SLC1A3 is highly expressed in the cerebellum and brainstem,2 and the sequence variants described in patients are thus far spread in different domains of the protein. Taken together, our findings demonstrate that SLC1A3 variants are associated with a spectrum of disorders similar to those seen in CACNA1A mutations. Our work expands the spectrum of SLC1A3 mutations beyond EA, illustrates the benefit of ACZ for hemiplegic migraine, and the utility of MRS as a biomarker for altered glutamate transport. An increase in Glx by 22% using MRS was found after treatment, with an acceptable SD for both measurements. Our findings are in contrast with the results reported by Zielman et al. among patients with migraine without aura.e-7 These authors found elevated interictal glutamate levels in the visual cortex. In another study by the same group, 7 T 1H-MRS was used for the first time in a group of 18 patients with FHM1 and FHM2.e-8 This study revealed reduced total N-acetylaspartate and total creatine in the cerebellum, but Glx/total creatine in the occipital lobe was not significantly altered. MRS studies on other patients harboring SLC1A3 variants are needed to evaluate whether a specific pattern of metabolite alterations exists for the disease spectrum associated with this gene.

Study funding

P. Svenningsson is a Wallenberg Clinical Scholar. M. Paucar's, T. Granberg's, and P. Svenningsson's research is supported by Region Stockholm. M. Paucar obtained funding from the Follin Foundation.

Disclosure

The authors reports no disclosures. Go to Neurology.org/NG for full disclosures.

Acknowledgment

The authors are grateful to the patients for their kind participation in this study. They thank Dr. Mattias Andréasson for evaluating the index case during a hemiplegic spell.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the authors.

  • Received December 19, 2019.
  • Accepted in final form May 28, 2020.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Adam MP,
    2. Ardinger HH,
    3. Pagon RA, et al.
    1. Jen JC
    . Familial Hemiplegic Migraine. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993-2019. Available from: www-ncbi-nlm-nih-gov.proxy.kib.ki.se/books/NBK1388/. Accessed May 14, 2015.
  2. 2.↵
    1. Jen JC,
    2. Wan J,
    3. Palos TP,
    4. Howard BD,
    5. Baloh RW
    . Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005;65:529–534.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. de Vries B,
    2. Mamsa H,
    3. Stam AH, et al
    . Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake. Arch Neurol 2009;66:97–101.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Kovermann P,
    2. Hessel M,
    3. Kortzak D, et al
    . Impaired K+ binding to glial glutamate transporter EAAT1 in migraine. Sci Rep 2017;7:13913.
    OpenUrl
  5. 5.↵
    1. Iwama K,
    2. Iwata A,
    3. Shiina M, et al
    . A novel mutation in SLC1A3 causes episodic ataxia. J Hum Genet 2018;63:207–211.
    OpenUrl
  6. 6.↵
    1. de Vries B,
    2. Haan J,
    3. Stam AH, et al
    . Alternating hemiplegia of childhood: no mutations in the glutamate transporter EAAT1.Neuropediatrics 2006;37:302–304.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Graves TD,
    2. Hanna MG
    . Episodic ataxia: SLC1A3 and CACNB4 do not explain the apparent genetic heterogeneity. J Neurol 2008;255:1097–1099.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Pelzer N,
    2. Haan J,
    3. Stam AH, et al
    . Clinical spectrum of hemiplegic migraine and chances of finding a pathogenic mutation. Neurology 2018;90:e575–e582.
    OpenUrlPubMed
  9. References e-1 to e-8 can be accessed via http://doi:10.5061/dryad.v41ns1rsd.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement